Hybrigenics receives first patent grant on chemical inhibitors of Ubiquitin-Specific Proteases

18-Dec-2008 - France

Hybrigenics, a bio-pharmaceutical company with a focus on research and development of new cancer treatments and specialized in protein interactions, announced it has been granted the first in a series of patent applications covering the company's proprietary chemical inhibitors of Ubiquitin-Specific proteases (USPs).

Proteases play a key role in a number of pathological processes and several protease inhibitors are already available as drugs (for example, ACE-inhibitors for hypertension and HIV-1 proteases inhibitors in AIDS). Ubiquitin-Specific Proteases are proteases responsible for the recycling of proteins. Inhibiting the recycling of oncoproteins (proteins involved in the development of cancer) will force their degradation and it is expected that this will slow-down the progression of certain cancers.

The granting of this patent extends the intellectual property portfolio of Hybrigenics: it is its first patent in the field of innovative small molecules with drug potential. This new patent further indicates Hybrigenics' progress towards pharmaceutical and therapeutic applications, moving downstream of the drug discovery pipeline after having focused on target research.

The recently granted European patent EP1749822 will subsequently be registered in 32 European countries. The corresponding worldwide application under the "Patent Cooperation Treaty" (PCT) is under way to extend further its geographical coverage, in particular to include the USA. Hybrigenics expects a rapid growth of its patenting activity around USPs and their inhibitors to strengthen its pioneer position in the field.

"This patent clearly positions Hybrigenics as a company with its own intellectual property in the field of a new class of potential innovative pharmaceutical ingredients," said Rémi Delansorne, CEO at Hybrigenics.

Other news from the department research and development

Most read news

More news from our other portals

Is artificial intelligence revolutionizing the life sciences?

Last viewed contents

Aastrom Biosciences and Zellera AG Announce the Initiation of a Clinical Trial for Bone Grafting in Spain - Aastrom's Proprietary TRCs to be Utilized in Second European Clinical Study to Treat Major Bone Fractures

Movetis Announces Start of a Phase IIa trial for M0002 in Ascites

Addex Achieves Second Milestone in Parkinson's Disease Collaboration with Merck & Co., Inc. - Data Confirm Non-Dopaminergic Approach to Treating Parkinson's Disease

BioInvent extends antibody collaboration with Japanese pharmaceutical partner - Lead candidate for inflammation to progress into preclinical development

Orexo's stock market move sends positive signal for biotech industry

PerkinElmer, Inc. and Corning Incorporated Announce Strategic Collaboration for the Advancement of Label-Free Technologies - Strategic agreement to develop next-generation platforms for Life Sciences research

Oxford BioTherapeutics Appoints Michael Moore as Chairman

Lundbeck enters into drug discovery collaboration with Zenobia and Vernalis

YM BioSciences USA cleared by US FDA to initiate Phase II clinical trial of nimotuzumab in children with brain cancer

M&A - The trials and tribulations - Former Schering & Plough CEO speaks out about the pharmaceutical Industry. Where they went wrong and the solutions, which lead to the successful sale

Lab21 Announces Positive Results for Aspergillus Detection in Critical Care and Haematology Patients